How Some Manufacturers Are Navigating COVID-19 Pharma Supply Chain Challenges
Gilead, Vetter, Lonza and academic experts share what they’re focusing on to keep producing drugs during the pandemic.
You may also be interested in...
Experts describe the agile, localized supply chains that will emerge, only perhaps to be forgotten just-in-time for the next crisis.
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?